In the context of BRAF/MEK inhibitors, the main cardiovascular side effects to be aware of are hypertension, pulmonary embolism, QTc prolongation, and cancer therapy–related cardiac dysfunction.4 Here, MAP2K7 is linked to pulmonary embolism.